CHEMILUMINESCENCE IMMUNOASSAY MARKET ANALYSIS

Chemiluminescence Immunoassay Market Size and Trends

Global chemiluminescence immunoassay market is estimated to be valued at USD 13.11 Bn in 2024 and is expected to reach USD 20.50 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.6% from 2024 to 2031.

To learn more about this report, request sample copy

The market trends driving the global chemiluminescence immunoassay market growth includes increasing disease prevalence, rising healthcare expenditure across developing nations, growing demand for clinical diagnostics to detect chronic diseases such as cancer, cardiovascular diseases, and infectious diseases. Furthermore, advancement in chemiluminescence immunoassay instruments, tools and reagents allowing fast and reliable detection of a wide range of analytes from small molecules to larger proteins through high sensitivity are witnessing increased adoption rate especially in hospitals and diagnostic laboratories, thus, driving the chemiluminescence immunoassay market growth.

Market Driver – Growing Prevalence of Chronic Diseases

Rising incidence of chronic and infectious diseases across the globe has boosted demand for chemiluminescence immunoassay testing. According to various estimates by healthcare experts and researchers, chronic diseases have now overtaken infectious illnesses as the major cause of mortality worldwide. Lifestyle changes such as unhealthy eating habits, lack of physical activity, rising stress levels and smoking have majorly contributed to staggering increase in conditions like cancer, diabetes, cardiovascular diseases and respiratory illnesses. As people are now living longer with these chronic illnesses, there has been rising need for frequent medical monitoring and screening tests. Chemiluminescence immunoassays provide accurate, precise and timely diagnosis of various chronic conditions. These assays are extensively used in hospitals and diagnostic labs for detecting cardiac marker enzymes to aid in the diagnosis of heart attacks. CLIA tests play a pivotal role in monitoring liver function, screening for hepatitis and other infectious agents that could lead to liver diseases. CLIA is also a preferred diagnostic methodology for endocrinological conditions like hyperthyroidism due to its high sensitivity. Growing geriatric population prone to age-related illnesses has also boosted demand for such assays. Due to rising chronic disease prevalence worldwide, healthcare providers are incorporating more chemiluminescence immunoassays in their practice to facilitate improved patient management.

Technological advancements in CLIA diagnostic platforms

Technological advancements are drastically transforming the chemiluminescence immunoassay (CLIA) diagnostic platforms. . Several innovative CLIA analyzers have widened the scope of CLIA testing. The new generation fully automated, high throughput CLIA analyzers offer enhanced sensitivity, specificity, faster turn-around-time and expanded assay menus as compared to conventional immunoassay technologies. For instance, as per World Health Organization in 2022, the Liaison range of CLIA analyzers by DiaSorin can perform a wide variety of routine and specialty tests including therapeutic drug monitoring, endocrinology, oncology, infectious diseases from a small patient sample volume in a single analytical run. (Furthermore, software and digital innovations are revolutionizing the CLIA diagnostic platforms. Many new systems are integrated with artificial intelligence (AI) and machine learning capabilities. This allows automated interpretation of test results, flagging of outliers, improved quality control, customized report generations and remote diagnostics. Cloud connectivity in some systems ensures real-time data access for clinicians from different locations. For instance, the Affinity total laboratory automation solution from Siemens Healthineers uses AI to automate repetitive tasks, standardized workflows and predictive maintenance to maximize efficiency. . According to the data published by the United Nations, non-communicable diseases and healthcare needs of an ageing global population will rise substantially in the future. COVID-19 pandemic witnessed exponential increase in infectious disease testing worldwide using CLIA platforms. This further underscores the necessity of rapid, automated and high-throughput CLIA technology for quality diagnostic services.